Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced Non-small Cell Lung Cancer Alone and in Combination With Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Bladder cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer
- Focus Therapeutic Use
- 03 Nov 2017 Planned number of patients changed from 120 to 90.
- 28 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 18 Mar 2016 New trial record